BST02
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 5, 2023 (NCT06173726)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- tRNA(Ile)-lysidine synthaseSupplementation
supplementation - TILs
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06526832 | Phase 1 | Jul 4, 2024 | BioSyngen Pte Ltd, Sun Yat-Sen University |
| NCT06173726 | Early Phase 1 (Phase 1) | Dec 5, 2023 | BioSyngen Pte Ltd, China Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioSyngen Pte Ltd | For profit | 2 | 2 | 1 | 2023 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1